Minireviews
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. May 26, 2016; 8(5): 327-332
Published online May 26, 2016. doi: 10.4330/wjc.v8.i5.327
P2Y12-ADP receptor antagonists: Days of future and past
Marc Laine, Franck Paganelli, Laurent Bonello
Marc Laine, Franck Paganelli, Laurent Bonello, Cardiology Department, CHU NORD, Chemine des Bourrely, 13015 Marseille, France
Author contributions: Laine M is the main author; Bonello L and Paganelli F reviewed and revised the manuscript.
Conflict-of-interest statement: Marc Laine has received consulting fees and lecture fees from AstraZeneca. Laurent Bonello has received consulting fees, research grant and lecture fees from AstraZeneca. Franck Paganelli has consulting fees from AstraZeneca.
Open-Access: This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Marc Laine, MD, Cardiology Department, CHU NORD, Chemine des Bourrely, AP-HM, 13015 Marseille, France. marc.laine@ap-hm.fr
Telephone: +33-4-91968858 Fax: +33-4-91968979
Received: May 4, 2015
Peer-review started: May 12, 2015
First decision: July 27, 2015
Revised: December 23, 2015
Accepted: January 21, 2016
Article in press: January 22, 2016
Published online: May 26, 2016
Processing time: 381 Days and 22.9 Hours
Core Tip

Core tip: Antiplatelet therapy in coronary artery disease has dramatically changed during the past few years. From ticlodipine to cangrelor, the present review summarizes the results of the main studies dealing with this hot topic of cardiology.